Update on propranolol for infantile hemangioma: Where are we now?

Amanda A. Cyrulnik, Sharon A. Glick

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.

Original languageEnglish (US)
Pages (from-to)e16-e25
JournalNeoReviews
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Hemangioma
Propranolol
Natural History
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Update on propranolol for infantile hemangioma : Where are we now? / Cyrulnik, Amanda A.; Glick, Sharon A.

In: NeoReviews, Vol. 16, No. 1, 01.01.2015, p. e16-e25.

Research output: Contribution to journalArticle

Cyrulnik, Amanda A. ; Glick, Sharon A. / Update on propranolol for infantile hemangioma : Where are we now?. In: NeoReviews. 2015 ; Vol. 16, No. 1. pp. e16-e25.
@article{eaafa96898f54aa99aa138b2e76c8590,
title = "Update on propranolol for infantile hemangioma: Where are we now?",
abstract = "The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.",
author = "Cyrulnik, {Amanda A.} and Glick, {Sharon A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1542/neo.16-1-e16",
language = "English (US)",
volume = "16",
pages = "e16--e25",
journal = "Pediatrics in Review",
issn = "0191-9601",
publisher = "American Academy of Pediatrics",
number = "1",

}

TY - JOUR

T1 - Update on propranolol for infantile hemangioma

T2 - Where are we now?

AU - Cyrulnik, Amanda A.

AU - Glick, Sharon A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.

AB - The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.

UR - http://www.scopus.com/inward/record.url?scp=84920413948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920413948&partnerID=8YFLogxK

U2 - 10.1542/neo.16-1-e16

DO - 10.1542/neo.16-1-e16

M3 - Article

AN - SCOPUS:84920413948

VL - 16

SP - e16-e25

JO - Pediatrics in Review

JF - Pediatrics in Review

SN - 0191-9601

IS - 1

ER -